Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, has broken ground on its new development and manufacturing facility in Louisville, CO.   “Manufacturing is a critical strategic component of Umoja’s approach to delivering the future of cancer immunotherapies, ensuring our treatments are widely accessible in a...